Gaboxadol Monohydrate Polymorphs for Corrosion-Free Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional pharmaceutical formulations of gaboxadol hydrochloride salts face corrosion issues during production, and there is a need for novel forms that can be reliably incorporated into oral dosage forms without compromising stability or bioavailability.
Innovation Solution
Development of novel polymorphic forms of gaboxadol monohydrate, specifically forms III and IV, characterized by distinct X-ray powder diffraction patterns and solid-state NMR spectra, which are prepared through specific solvent and pH-controlled processes, allowing for stable incorporation into pharmaceutical formulations without corrosion risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If gaboxadol hydrochloride salt is used in conventional pharmaceutical formulations, then the compound can be incorporated into oral dosage forms, but corrosion problems occur during production
Solution Approach 1:
The patent changes the physical and chemical parameters of gaboxadol by transitioning from the hydrochloride salt form to the free base form, and further to specific polymorphic forms (Form I and Form II) with distinct crystal structures. This parameter change eliminates corrosion issues while maintaining pharmaceutical efficacy and manufacturability in oral dosage forms
Solution Approach 2:
The patent utilizes phase transitions by describing multiple polymorphic forms of gaboxadol with different crystalline arrangements. The invention specifically identifies Form I and Form II as stable polymorphic forms that can be produced through controlled crystallization processes, replacing the corrosive hydrochloride salt form
2Adaptability or versatility
If the morphological form of gaboxadol is not held constant during clinical and stability studies, then the dosage form can be flexible in formulation, but the exact dosage used or measured may not be comparable from one lot to the next
Solution Approach 1:
The patent establishes specific polymorphic forms (Form I and Form II) with defined crystal structures and physical properties. By controlling the morphological form through specific crystallization conditions, the invention ensures consistent dosage composition across batches while maintaining formulation flexibility
Solution Approach 2:
The patent applies local quality by specifying particular polymorphic forms with distinct crystallographic properties for different aspects of the formulation. Form I and Form II are characterized by specific unit cell parameters and packing arrangements that provide both formulation adaptability and dosage precision
3Ease of manufacture
If acid addition salts of gaboxadol are used, then the compound can be incorporated into pharmaceutical formulations, but corrosion problems arise when conventional techniques and equipment are employed
Solution Approach 1:
The patent fundamentally changes the chemical parameter by replacing the hydrochloride salt form with the free base form, and further refines it to specific polymorphic forms. This parameter change eliminates the corrosive properties associated with acid addition salts while preserving pharmaceutical formulation capabilities
Solution Approach 2:
The patent converts the potentially harmful corrosive property of acid addition salts into a benefit by using the free base form and specific polymorphic forms that are non-corrosive. The invention turns the previous problem (corrosion from hydrochloride salts) into a solution by selecting polymorphic forms with favorable chemical properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymorphic forms of gaboxadol monohydrate provide enhanced stability and bioavailability, enabling their use in pharmaceutical compositions suitable for oral dosage forms without corrosion issues, maintaining equivalent bioavailability to acid addition salts.
Implementation Method 1
characterized by characteristic absorption bands obtained from an X-ray powder diffraction pattern at spectral d-spacings of 5.1 and 3.7 angstroms
Implementation Method 2
Gaboxadol monohydrate polymorphic form III is further characterized by a solid state 13C nuclear magnetic resonance spectrum with a peak at 16.9 ppm
Data Source
AI summary
The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.